C. A. Lerchenmuller

发表

Gender and tumor location as predictors for efficacy: Influence on endpoints in first-line treatment with FOLFIRI in combination with cetuximab or bevacizumab in the AIO KRK 0306 (FIRE3) trial.

W. Scheithauer, M. Stauch, V. Heinemann, 2014 .

O-0030INDEPENDENT RADIOLOGICAL EVALUATION OF OBJECTIVE RESPONSE EARLY TUMOR SHRINKAGE, AND DEPTH OF RESPONSE IN FIRE-3 (AIO KRK-0306)

W. Scheithauer, M. Stauch, V. Heinemann, 2014 .

Temsirolimus in Combination with Bendamustine and Rituximab (BeRT) for the Treatment of Relapsed Mantle Cell and Follicular Lymphoma: Final Phase I/II Results

M. Dreyling, P. Borchmann, G. Hess, 2016 .

Everolimus (RAD) as treatment in breast cancer patients with bone metastases only: Results of the phase II RADAR study.

S. Loibl, N. Harbeck, S. Kuemmel, 2012 .

Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenström's Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN trial)

R. Greil, C. Buske, A. Hinke, 2019, Blood.

Trastuzumab (TRA) in combination with different first-line chemotherapies for treatment of HER2-positive metastatic gastric or gastroesophageal junction cancer (MGC): Findings from the German noninterventional observational study HerMES.

V. Kaechele, S. Al-Batran, V. Petersen, 2012 .

Capecitabine (Cap) combined with bevacizumab (Bev) with or without vinorelbine (Vin) in first-line metastatic breast cancer (MBC): First safety results from the randomized CARIN trial.

T. Decker, S. Hegewisch‐Becker, C. Steffens, 2011, Journal of Clinical Oncology.

Subgroup analyses of a randomized sequential open-label study (SWITCH) to evaluate efficacy and safety of sorafenib (SO)/sunitinib (SU) versus SU/SO in the treatment of metastatic renal cell cancer (mRCC).

M. Santis, W. Vervenne, W. Freier, 2014 .

Two years rituximab maintenance vs. observation after first line treatment with bendamustine plus rituximab (B-R) in patients with marginal zone lymphoma (MZL): Results of a prospective, randomized, multicenter phase 2 study (the StiL NHL7-2008 MAINTAIN trial).

R. Greil, A. Ganser, A. Hinke, 2018 .

Somatic DNA mutations, tumor mutational burden (TMB), and MSI Status: Association with efficacy in patients (pts) with metastatic colorectal cancer (mCRC) of FIRE-3 (AIO KRK-0306).

W. Scheithauer, V. Heinemann, T. Decker, 2018 .

Influence of adjuvant pretreatment on outcome of FIRE-3 (AIO KRK-0306): A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients.

W. Scheithauer, M. Stauch, V. Heinemann, 2015 .

835PUPDATED OS ANALYSIS, MULTIVARIATE AND QTWIST ANALYSIS OF A RANDOMIZED SEQUENTIAL OPEN-LABEL STUDY (SWITCH) TO EVALUATE EFFICACY AND SAFETY OF SORAFENIB (SO) / SUNITINIB (SU) VERSUS SU/SO IN THE TREATMENT OF METASTATIC RENAL CELL CANCER (MRCC).

W. Vervenne, W. Freier, S. Pahernik, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Per protocol analysis and final OS update of the FIRE-3 (AIO KRK-0306) study comparing FOLFIRI plus cetuximab vs. FOLFIRI plus bevacizumab.

W. Scheithauer, V. Heinemann, T. Decker, 2018 .

Consensus molecular subgroups (CMS) of colorectal cancer (CRC) and first-line efficacy of FOLFIRI plus cetuximab or bevacizumab in the FIRE3 (AIO KRK-0306) trial

W. Scheithauer, P. Wirapati, V. Heinemann, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).

V. Heinemann, S. Kasper, C. Junghanss, 2021, Journal of Clinical Oncology.

Phase III randomized sequential open-label study to evaluate efficacy and safety of sorafenib (SO) followed by sunitinib (SU) versus sunitinib followed by sorafenib in patients with advanced/metastatic renal cell carcinoma without prior systemic therapy (SWITCH Study): Safety interim analysis result

M. Staehler, M. Santis, W. Vervenne, 2012 .